Back to All Events

Intrommune Private Investor Briefing - Virtual

Intrommune Private Investor Briefing - Virtual

by CONNECTpreneur Investor Network

MONDAY, March 23, 11:30 am EDT

Dear Investors,

Opus8 is hosting a virtual, invitation-only private investor briefing featuring Intrommune, a consumer health company pioneering a new approach to peanut allergy prevention.

Intrommune’s patented platform delivers allergens through a familiar daily routine—brushing your teeth. By administering controlled exposure through toothpaste, the technology trains the immune system and aims to prevent life-threatening peanut allergies through a simple, consumer-friendly delivery method.


Company Overview

Intrommune is developing a consumer-grade immunotherapy platform designed to make allergy prevention safe, simple, and scalable. By combining biotech-grade science with a routine daily behavior, the company is creating a new category in preventive allergy care. With early clinical validation and commercial traction already underway, Intrommune is positioned at the intersection of healthcare innovation and consumer accessibility.

What Differentiates Intrommune

• Clinically Validated Approach — In the Phase 1 peanut allergy study, patients achieved 97% adherence with zero dropouts and zero cases of anaphylaxis

• Early Commercial Traction — The company began generating revenue through its distribution channels in November 2025

• Large and Underserved Market — More than 33 million Americans suffer from food allergies, with limited treatment options currently available

• First-Mover Consumer Platform — The only biotech-grade allergy immunotherapy delivered in a consumer-ready toothpaste format

• Experienced Leadership — Led by seasoned executives and advisors from across biotech, healthcare, and consumer health

Event Details:

Date: March 23

Time: 11:30 AM EDT

Location: Online via Zoom

Please note that this meeting is for DIRECT and ACTIVE Accredited investors only. All RSVPs must be pre-registered on this Eventbrite site with the investor criteria filled out. All RSVPs are subject to review and approval. We will provide a confirmation email and a calendar invitation after you register.

Request investor materials by contacting Avery North at anorth@opus8.com

Thanks much and all the best,

Tien Wong

CEO,

Opus8, Inc.

twong@opus8.com

Previous
Previous
March 17

Saltenna Private Investor Briefing - Virtual

Next
Next
March 31

ARC Medical Private Investor Briefing - Virtual